
    
      This study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics
      of GSK1292263 when co-administered with metformin. The study will be in 2 parts. Part A will
      determine the PK of GSK1292263 following single day dosing of type 2 diabetes (T2DM) subjects
      on metformin. Part B will investigate the effects of 14d of co-dosing of GSK1292263 BID, 50mg
      BID of sitagliptin or placebo to 48 T2DM subjects taking metformin.
    
  